- Home
- LIEN vs FHTX Comparison
LIEN vs FHTX Comparison
Compare LIEN & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- FHTX
- Stock Information
- Founded
- LIEN 2021
- FHTX 2015
- Country
- LIEN United States
- FHTX United States
- Employees
- LIEN N/A
- FHTX N/A
- Industry
- LIEN
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- LIEN
- FHTX Health Care
- Exchange
- LIEN NYSE
- FHTX Nasdaq
- Market Cap
- LIEN 292.1M
- FHTX 237.4M
- IPO Year
- LIEN 2022
- FHTX 2020
- Fundamental
- Price
- LIEN $10.92
- FHTX $4.41
- Analyst Decision
- LIEN
- FHTX Strong Buy
- Analyst Count
- LIEN 0
- FHTX 5
- Target Price
- LIEN N/A
- FHTX $13.80
- AVG Volume (30 Days)
- LIEN 9.7K
- FHTX 170.9K
- Earning Date
- LIEN 11-07-2024
- FHTX 03-06-2025
- Dividend Yield
- LIEN 9.83%
- FHTX N/A
- EPS Growth
- LIEN N/A
- FHTX N/A
- EPS
- LIEN 0.67
- FHTX N/A
- Revenue
- LIEN $12,681,914.00
- FHTX $25,515,000.00
- Revenue This Year
- LIEN $71.81
- FHTX N/A
- Revenue Next Year
- LIEN $113.93
- FHTX $7.37
- P/E Ratio
- LIEN $16.63
- FHTX N/A
- Revenue Growth
- LIEN 22.94
- FHTX N/A
- 52 Week Low
- LIEN $7.61
- FHTX $2.70
- 52 Week High
- LIEN $13.38
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- FHTX 34.76
- Support Level
- LIEN N/A
- FHTX $4.13
- Resistance Level
- LIEN N/A
- FHTX $4.47
- Average True Range (ATR)
- LIEN 0.00
- FHTX 0.35
- MACD
- LIEN 0.00
- FHTX 0.07
- Stochastic Oscillator
- LIEN 0.00
- FHTX 30.77
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company's investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.